Filing Flows

Filing Flows › Vir Biotechnology (VIR) › Next earnings date

Vir Biotechnology (VIR) earnings: beat the estimate

Vir Biotechnology (VIR) reported on Nov 4, 2026 and beat the EPS estimate: −$0.57 against −$0.63 (+9.5%). It beat the EPS estimate in 40% of the quarters on record.

Last result+9.5% vs estimate
Beat rate40%

The last report

Vir Biotechnology reported revenue of $239M for the second quarter 2026 (197× Y/Y), net earnings $80.1M: License and collaboration revenue $239M, Grant revenue $11K. How it makes money → · Every quarter →

Vir Biotechnology: EPS against the estimate, last 5 reportsVir Biotechnology: EPS against the estimate, last 5 reportsEstimateReported−$0.86−$1.17Nov 25−$0.45−$0.31Feb 26$0.48−$0.85May 26$0.90$0.47Aug 26−$0.63−$0.57Nov 26
Latest (Nov 26): Estimate −$0.63, Reported −$0.57.

Vir Biotechnology's latest quarter

Vir Biotechnology, Q2 2026: revenue $239M (197× year over year), operating margin 30.7%, net earnings $80.1M, operating cash flow $123M. The chart follows the revenue to costs, profit and cash.

Questions

Did Vir Biotechnology beat earnings?

Vir Biotechnology (VIR) reported on Nov 4, 2026 and beat the EPS estimate: −$0.57 against −$0.63 (+9.5%).

When does VIR report earnings?

The next date is not set yet.

Does Vir Biotechnology usually beat earnings?

It beat the consensus EPS estimate in 40% of the quarters on record.

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.